Diffuse Large B-cell Lymphoma (DLBCL)

The patient, a resilient woman nearing 80 years of age, bravely faced the diagnosis of Diffuse Large B-cell Lymphoma (DLBCL), demonstrating remarkable courage in her battle against this aggressive form of cancer.

Despite her advanced age, she remained determined to overcome the challenges posed by her condition. However, within six months after achieving remission with first-line therapy, she experienced a relapse, underscoring the aggressive nature of her disease. Despite multiple attempts with second and third-line treatments, her cancer exhibited stubborn resistance, posing a significant challenge for her medical team.

Recognizing the urgency of her situation, the medical team embarked on a quest to explore alternative treatment options. The patient was enrolled in a clinical trial investigating CD19+22 CAR-T cell therapy, a cutting-edge approach that utilizes genetically engineered T cells to target cancer cells expressing specific antigens.

The results were nothing short of extraordinary. Just one month following the infusion of CD19+22 CAR-T cells, the patient achieved complete remission. This groundbreaking outcome not only halted the progression of her disease but also led to the successful eradication of cancer cells, marking a pivotal moment in her treatment journey.

Throughout the arduous process, the medical team provided unwavering support and care to the patient. From closely monitoring her response to therapy to managing any adverse events, they ensured her well-being remained the top priority.

Reflecting on her experience, the patient expressed profound gratitude for the compassionate care she received. "The dedication and expertise of my medical team were truly exceptional," she remarked. "Their personalized approach to treatment gave me hope when I needed it most."

The successful outcome of CD19+22 CAR-T cell therapy in achieving complete remission highlights its potential as a promising treatment option for refractory DLBCL patients. This case serves as a testament to the power of innovative therapies and personalized medicine in managing complex cancers, particularly in elderly patients like this courageous woman.

Before & 1 month after infusion